Wyeth announced that The Honourable George F. McGunnigle of the Hennepin County District Court in Minneapolis, Minnesota has granted Wyeth's motion for summary judgment on all claims and dismissed the case of Patricia Zandi v. Wyeth, which was scheduled for trial on January 28, 2008.

In rulings on the admissibility of plaintiff's expert testimony and on the motion for summary judgment, the court found that the plaintiff had not offered any scientifically valid evidence to support her claim that she developed breast cancer as a result of her use of Premarin and Prempro.

Judge McGunnigle held that plaintiff had "provided no evidence of a method generally accepted in the scientific community by which a doctor can determine the cause of breast cancer in an individual."

"In this case," the court elaborated, plaintiff's experts "purported to make a differential diagnosis. However, their attempt at differential diagnosis fails and is unreliable." The court concluded that "the scientific community has not accepted that breast cancer has a limited number of discrete and recognized possible causes such that ruling out one cause would implicate another."

"We are pleased with the Court's ruling and believe it was consistent with the body of scientific knowledge concerning hormone therapy and a proper application of the law," said Rebecca E. Moos, a partner with Bassford Remele, a Minneapolis firm representing Wyeth in the case.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide.